2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significanceCardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis
Hammer M, Tysarowski M, Fuss C, Bader A. Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis. Echocardiography 2025, 42: e70131. PMID: 40067334, DOI: 10.1111/echo.70131.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCardiac magnetic resonance imagingMagnetic resonance imagingAssociated with immune-related adverse eventsCardiac immune-related adverse eventsMechanisms of immune checkpoint inhibitorsICI-associated myocarditisICI-related myocarditisResonance imagingPersonalized cancer immunotherapySevere cardiovascular complicationsImmune tolerance pathwayCheckpoint inhibitorsCancer immunotherapyCardiac complicationsCombination therapyTumor cytotoxicityClinical presentationCardiovascular complicationsAdverse eventsTherapeutic efficacyOncological treatmentTherapeutic strategiesMyocarditisSafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitor initiationImmune checkpoint inhibitorsTreatment-related adverse eventsObjective response rateProgression-free survivalCardiac metastasisOverall survivalRetrospective studyAnti-cytotoxic T-lymphocyte antigen 4Dose of immune checkpoint inhibitorsEfficacy of immune checkpoint therapyAnti-programmed death-1International multicenter retrospective studyMulticenter international retrospective studyT-lymphocyte antigen-4Non-small cell lung cancerMedian follow-up timeClinical outcomes of patientsICI-based regimensMultiple cardiac metastasesSolid Tumors V.1.1Immune checkpoint therapyResponse Evaluation CriteriaInternational retrospective studyMulticenter retrospective studyDEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMA
Kashima S, Gupta R, Moritz V, Sadak K, Walker J, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMA. Urologic Oncology Seminars And Original Investigations 2025, 43: 22-23. DOI: 10.1016/j.urolonc.2024.12.057.Peer-Reviewed Original ResearchRCC tumor microenvironmentPatient-derived tumor modelsRenal cell carcinomaImmune checkpoint inhibitorsT cell functionTumor microenvironmentT cellsEnzyme-linked immunosorbent assayFlow cytometryTumor fragmentsTumor samplesCytokine productionImpact of immune checkpoint inhibitorsAnti-PD-1 monoclonal antibodyCD4+CD25+ regulatory T cellsResection of renal cell carcinomaSurgical resection of renal cell carcinomaCD8+ T cell populationsAnti-PD-1 antibodyMetastatic renal cell carcinomaCD20+ B cellsActivated CD8 T cellsEvaluate T cell activationT cell cytokine productionStudy of renal cell carcinomaPresence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.
Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discovery 2025, of1-of21. PMID: 39992403, DOI: 10.1158/2159-8290.cd-24-0991.Peer-Reviewed Original ResearchTertiary lymphoid structuresRenal cell carcinomaCD8+ T cellsAnti-PD1 monotherapyImmune checkpoint inhibitorsT cellsCell carcinomaLymphoid structuresClinical outcomesClinical response to PD-1 blockadeTreatment of advanced renal cell carcinomaResponse to PD-1 blockadePresence of tertiary lymphoid structuresAdvanced renal cell carcinomaTissue-resident T cellsPD-1 blockadePhase II clinical trialPD-1 pathwayCheckpoint inhibitorsICI resistancePD-1Responding patientsTumor microenvironmentTherapeutic responseTissue-residentInpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.
Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, op2400788. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsOverall survivalICI administrationSolid malignanciesPatients treated with immune checkpoint inhibitorsAdministration of immune checkpoint inhibitorsMultivariate Cox proportional hazards model analysisResponse to ICI therapyCox proportional hazards model analysisProportional hazards model analysisAdvanced solid malignanciesKaplan-Meier methodOutcomes of patientsInstitutional electronic medical recordsHazards model analysisCox proportional hazards modelsProportional hazards modelCheckpoint inhibitorsICI therapyMedian OSICI initiationICI useRetrospective studyClinical outcomesClinicodemographic variablesDose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.
Agarwal R, Ebrahimi H, Zengin Z, Barragán Carrillo R, Dizman N, Zugman M, Jaime-Casas S, Meza L, Li X, Hsu J, Castro D, Mercier B, Lee P, Takahashi M, Tripathi A, Dorff T, Caporaso G, Lee K, Pal S, Chehrazi-Raffle A. Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study. Journal Of Clinical Oncology 2025, 43: tps611-tps611. DOI: 10.1200/jco.2025.43.5_suppl.tps611.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsProgression-free survivalMaximum tolerated dosePhase I studyRenal cell carcinomaDose levelsCell carcinomaClinical outcomesEfficacy of immune checkpoint inhibitorsMetastatic renal cell carcinoma patientsModulation of immune pathwaysImmune checkpoint inhibitor therapyStandard-of-care treatmentIMDC risk groupsPlanned dose levelsCombination of nivolumabDose-limiting toxicityDose-escalation designDose-escalation studyECOG performance statusDose-finding studyGut microbiomeCheckpoint inhibitorsDose escalationINTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).
Motzer R, Braun D, Powles T, Gurney H, Fong L, George D, Haas N, McDermott D, Shuch B, Meehan R, Posadas T, Wu S, Elfiky A, Choueiri T. INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: tps610-tps610. DOI: 10.1200/jco.2025.43.5_suppl.tps610.Peer-Reviewed Original ResearchRenal cell carcinomaWeeks prior to randomizationAdverse eventsTumor-specific T-cell activationResection of metastatic lesionsAdjuvant treatment of patientsIncreased risk of recurrenceStage III/IV melanomaImmune checkpoint inhibitorsDisease-free survivalMetastasis-free survivalPhase 2 trialRisk of recurrenceDouble-blind studyT cell activationTreatment of patientsNovel combination strategiesDose of treatmentAdjuvant pembrolizumabAdjuvant settingCheckpoint inhibitorsPapillary histologyPD-1Sarcomatoid featuresMetastatic lesionsDatopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
Meric-Bernstam F, Alhalabi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira A, Salkeni M, Gao X, Tolcher A, Bhave M, Doroshow D, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Journal Of Clinical Oncology 2025, 43: 663-663. DOI: 10.1200/jco.2025.43.5_suppl.663.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsBlinded independent central reviewProgression-free survivalDuration of responsePartial responseIndependent central reviewComplete responseConfirmed ORRUrothelial cancerCentral reviewMedian duration of responseMedian progression-free survivalResponse rateImmune checkpoint inhibitorsInterstitial lung disease/pneumonitisTreatment-related AEsMedian follow-upSolid tumor typesAntibody-drug conjugatesPrimary study objectiveCheckpoint inhibitorsDose interruptionPretreated ptsStable diseaseData cutoffComprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).
Kashima S, Xu W, Canniff J, Saliby R, Sun M, Lee G, Machaalani M, Signoretti S, McGregor B, McKay R, Choueiri T, Braun D. Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 562-562. DOI: 10.1200/jco.2025.43.5_suppl.562.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaRenal cell carcinoma patientsICI-based therapyNon-respondersPatients treated with ICI monotherapyResistance to immune checkpoint inhibitorsHLA-BICI respondersAdvanced renal cell carcinomaImmune cells to tumorsTGF-B pathwayTreatment evolutionCells to tumorsSustained immune activationPlasma samplesProfiling of plasma samplesCornerstone of treatmentPaired samplesPlasma proteomic analysisAssociated with responseAnti-tumor inflammationICI monotherapyInvestigated plasma proteinsCheckpoint inhibitorsMetabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.Peer-Reviewed Original ResearchProgression-free survivalImmune checkpoint inhibitorsRenal cell carcinomaComplete responsePartial responseProgressive diseaseWhole-exome sequencingMetabolic gene signatureOverall survivalVEGF inhibitorsCell carcinomaGene set enrichment analysisER patientsSignature scorePatients treated with immune checkpoint inhibitorsResponse to immune checkpoint inhibitionResponse to ICIExceptional responseAdvanced clear cell renal cell carcinomaProgression-free survival predictorsProlonged progression-free survivalMetastatic renal cell carcinomaMultivariate Cox proportional hazards analysisGene signaturePhase III clinical trialsInvestigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).
Madsen K, Labaki C, Saad E, Alchoueiry M, Bi K, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Heng D, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC). Journal Of Clinical Oncology 2025, 43: 583-583. DOI: 10.1200/jco.2025.43.5_suppl.583.Peer-Reviewed Original ResearchInternational Metastatic RCC Database ConsortiumMetastatic clear cell RCCProgression-free survivalOverall survivalClear cell RCCCell of originMTOR inhibitorsTumor cellsChRCC tumorsEpithelial cellsScRNA-seq analysisCell RCCMetastatic ChRCCResponse to immune checkpoint inhibitorsDistal tubulesMechanisms of therapeutic responseChromophobe renal cell carcinomaTreated with mTOR inhibitorsResponse to mTOR inhibitorsImmune checkpoint inhibitorsScRNA-seqA intercalated cellsB intercalated cellsImproved overall survivalEvaluate survival outcomesSurvival of patients with metastatic renal cell carcinoma with or without brain metastases.
Hurwitz M, Considine B, Hasson N, Savion Gaiger N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. Journal Of Clinical Oncology 2025, 43: 476-476. DOI: 10.1200/jco.2025.43.5_suppl.476.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsClear cell RCCRenal cell carcinomaImmune checkpoint inhibitor therapyMetastatic clear cell RCCBrain metastasesOverall survivalCell carcinomaImmune checkpoint inhibitor eraPrevalence of brain metastasesMultivariate Cox proportional hazards modelAssociated with poor survivalMedian overall survivalAssociated with poor prognosisCompare overall survivalImproved overall survivalAdverse prognostic indicatorDevelopment of BMSurvival of patientsKaplan-Meier analysisYale Cancer CenterRetrospective cohort studyCox proportional hazards modelsProportional hazards modelUtility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer.
Linhares S, Srikumar T, Shin C, Mathur M, Mongiu A, Leeds I, Pantel H, Cecchini M. Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer. Journal Of Clinical Oncology 2025, 43: 45-45. DOI: 10.1200/jco.2025.43.4_suppl.45.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNeoadjuvant immune checkpoint inhibitorsPathological stageDMMR tumorsPMMR tumorsColon cancerSurgical resectionT stageRadiographic stagePathologic complete response rateUtilization of computed tomographyClinically staged patientsNode negative tumorsRate of understagingComplete response rateLocally advanced diseaseNode-positive diseaseClinical tumor stageNode-positive tumorsUpfront surgical resectionCorrelated to pathological stagingPrimary tumor growthLocalized colon cancerLow relapse rateEarly stage tumorsClinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-targeted therapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapyImmunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon Y, Eid M, Sheshdeh A, Krajewski K, Büttner F, Schwab M, Heng D, Casellas R, Rai K, Zacharias Millward N, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri T, Braun D, Shukla S. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nature Cancer 2025, 6: 372-384. PMID: 39789182, DOI: 10.1038/s43018-024-00896-w.Peer-Reviewed Original ResearchConceptsTertiary lymphoid structuresVascular endothelial growth factorRenal cell carcinomaCell carcinomaCytotoxic T-lymphocyte-associated protein 4 inhibitorsResponse to immune checkpoint inhibitionExceptional responseMetastatic clear cell renal cell carcinomaStandard-of-care immunotherapiesTertiary lymphoid structure formationCytotoxic T cell responsesClear cell renal cell carcinomaIO-based treatmentsTreatment-naive personsImmune checkpoint inhibitionImmune checkpoint inhibitorsCell renal cell carcinomaT cell responsesT-cell-directedEndothelial growth factorCell death proteinAntitumor immunityCheckpoint inhibitionCheckpoint inhibitorsNeoantigen loadHow to Use Imaging: Complex Cases of Atherosclerosis, Myocardial Inflammation, and Cardiomyopathy in Cardio-Oncology
Khattab M, Baig M, Zarif T, Barac A, Ferencik M, Henry M, Lopez-Mattei J, Redheuil A, Salem J, Scherrer-Crosbie M, Yang E, Baldassarre L. How to Use Imaging: Complex Cases of Atherosclerosis, Myocardial Inflammation, and Cardiomyopathy in Cardio-Oncology. Circulation Cardiovascular Imaging 2025, 18: e015981. PMID: 39772610, DOI: 10.1161/circimaging.124.015981.Peer-Reviewed Original ResearchConceptsCardio-oncologyCases of atherosclerosisCardiac magnetic resonance imagingCoronary computed tomography angiographySingle-photon emission computed tomographyImmune checkpoint inhibitorsLeft ventricular dysfunctionMultimodality cardiac imagingTyrosine kinase inhibitorsCardiac imaging modalitiesComputed tomography angiographyRisk of cardiovascular diseaseEmission computed tomographyPositron emission tomographyMagnetic resonance imagingCheckpoint inhibitorsVentricular dysfunctionMyocardial inflammationCoronary vasospasmAccelerated atherosclerosisKinase inhibitorsPatient populationDiagnosing such pathologiesCancer therapyCardiac imaging
2024
Mechanisms of immunotherapy resistance in small cell lung cancer
Nie Y, Schalper K, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resistance 2024, 7: n/a-n/a. PMID: 39802951, PMCID: PMC11724353, DOI: 10.20517/cdr.2024.154.Peer-Reviewed Original ResearchSmall-cell lung cancerImmune checkpoint inhibitorsSociety for Immunotherapy of CancerImmunotherapy resistanceTumor microenvironmentPrimary resistanceAcquired resistancePrimary resistance to immune checkpoint inhibitorsLung cancerResistance to immune checkpoint inhibitorsMechanisms of immunotherapy resistanceSmall cell lung cancerImmunosuppressive immune cellsImmunotherapy to chemotherapyResistance to immunotherapySociety for ImmunotherapyImmunotherapy of cancerAggressive neuroendocrine tumorCell lung cancerCheckpoint inhibitorsTumor immunogenicityEffective immunotherapyNeuroendocrine tumorsPoor prognosisAntigen presentationTargeting immune evasion in hepatocellular carcinoma-initiating cells
Sirera R, Beltrán-Visiedo M, Galluzzi L. Targeting immune evasion in hepatocellular carcinoma-initiating cells. Trends In Immunology 2024, 46: 4-6. PMID: 39721855, DOI: 10.1016/j.it.2024.12.002.Peer-Reviewed Original ResearchMismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome
Khandakar B, Lacy J, Gibson J. Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome. Clinical Genetics 2024, 107: 469-474. PMID: 39660603, DOI: 10.1111/cge.14670.Peer-Reviewed Original ResearchLynch syndromeColorectal carcinomaResponse to immune checkpoint inhibitorsImpact of molecular classificationImmune checkpoint inhibitorsColorectal carcinoma developmentMismatch repairMicrosatellite instabilityResponse to treatmentPMS2 variantsCheckpoint inhibitorsPembrolizumab treatmentPathological responsePatient AGermline variantsColorectal adenocarcinomaMismatch repair proteinsMolecular classificationLS patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply